MedTrace Logo

Prospective Analysis of Value of Contrast-enhanced Sonography During Biopsies of Focal Liver Masses

NCT03040323 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 83

Last updated 2019-08-08

Study results available
· View outcomes & findings →

Summary

The investigators plan to compare complication and success rates between two methods of ultrasound guidance for biopsy of liver lesions, contrast-enhanced and the current protocol without contrast.

Conditions

  • Liver Biopsy

Interventions

DRUG

Lumason 60.7Mg Powder for Injection

Lumason 60.7Mg Powder for Injection injected prior to ultrasound-guided biopsy

DRUG

Placebos

Placebos injected prior to ultrasound-guided biopsy

Sponsors & Collaborators

  • Indiana University

    lead OTHER

Principal Investigators

  • Kumar Sandrasegaran, MD · Indiana University

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-22
Primary Completion
2018-06-30
Completion
2018-07-06
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03040323 on ClinicalTrials.gov